Dr Reddys Laboratories (RDY) Assets Average (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Assets Average of $6.0 billion for Q1 2026, up 14.63% year-over-year from $5.2 billion in Q1 2025, and up 14.63% quarter-over-quarter from $5.2 billion in Q1 2025.
Dr Reddys Laboratories (RDY) Assets Average (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Assets Average history runs 3 years deep, the most recent figure standing at $6.0 billion for Q1 2026.
- In Q1 2026, Assets Average rose 14.63% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $6.0 billion (up 14.63% YoY), while the FY2026 annual figure was $6.0 billion, up 14.63% from the prior year.
- Assets Average for Q1 2026 stood at $6.0 billion, up from $5.2 billion in the prior quarter.
- The five-year high for Assets Average was $6.0 billion in Q1 2026, with the low at $5.2 billion in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 5.97 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 4.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.97 Bn |
| Mar 31, 2025 | 5.21 Bn |
| Dec 31, 2009 | 1.64 Bn |
| Sep 30, 2009 | 1.74 Bn |